Advertisement

Topics

Companies Related to "Erratum metabolic regulator PGC1 suppresses prostate cancer metastasis" [Most Relevant Company Matches] RSS

15:53 EST 10th December 2018 | BioPortfolio

Here are the most relevant search results for "Erratum metabolic regulator PGC1 suppresses prostate cancer metastasis" found in our extensive corporate database of over 50,000 company records.

Showing "Erratum metabolic regulator PGC1 suppresses prostate cancer metastasis" Companies 1–25 of 2,600+

Extremely Relevant

Prostate Cancer Education Council

Prostate cancer remains the second-leading cause of cancer death in American men. More than 220,000 men will be diagnosed with prostate cancer this year and it is expected that 27,000 men will die from the disease. With more annual cases of prostate cancer than that of breast cancer among women, screening is imperative to ensure the health of the men of our nation.


Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world’s largest philanthropic source of support for accelerating the world’s most promising research for discovering better treatments and cures for prostate cancer. Founded in 1993, the PCF has raised nearly $400 million and provided funding to more than 1,500 researchers at nearly 200 institutions wor...

The Prostate Cancer Foundation

The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research focused on discovering better treatments and a cure for prostate cancer at every stage of diagnosis. Founded in 1993, the PCF has raised more than $370 million and provided funding to more than 1,500 research projects at nearly 200 instit...


Relevant

MetaStat, Inc.

MetaStat, Inc (OTCQB:MTST) is a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where syst...

Stratify Genomics, Inc.

Currently, there are 35,000 men annually who are unaware of a curable form of clinically significant prostate cancer. Relying solely on family history, 80% of prostate cancer cases would be missed. The most common screening tool, prostate-specific antigen (PSA) testing, has declined in usage due to controversial guidelines, which has led to a significant i...

Prostate Oncology Specialists, Inc.

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 217,730 new cases and approximately 32,050 men expected to die from the disease in 2010.

RC Cancer Centers

Each year thousands of patients from around the world and across the United States turn to RC Cancer Centers seeking a cure for their prostate cancer and learn why they are The Choice for Saving Lives. Founded in 1979, Radiotherapy Centers of Georgia, a division of RC Cancer Centers, has earned a reputation for being one of the country's top cancer treatment and research facilities because of its ...

Prostate Oncology Specialists,Inc.

Prostate Oncology Specialists is a medical group exclusively devoted to caring for men with prostate cancer. We have vast experience diagnosing and treating prostate cancer because 100% of our time is focused on managing men with this disease. Our physicians are board certified in both medical oncology and internal medicine and have made significant contributions to the scientific advancement in t...

Minomic International Ltd

Minomic International Ltd is an Australian immuno-oncology company specialising in therapeutics and diagnostics for prostate cancer and other cancers. Minomic has developed the in vitro diagnostic test called MiCheck® for the early detection of prostate cancer. Minomic is preparing to globally launch its first product, a novel prostate cancer blood test...

Coalition to Cure Prostate Cancer

The Coalition to Cure Prostate Cancer is a philanthropic organization that funds and accelerates advanced prostate cancer research in Canada. Beginning in 2011, the Coalition has identified unique strategies to invest in the most promising research programs that generate life-saving results. By channeling resources to Canada’s top scientific minds, red ...

Glactone Pharma AB

Glactone Pharma AB is developing a drug for the treatment of castration resistant prostate cancer. Research has shown that the natural product galiellalactone can modulate a signaling protein (STAT3) that is over activated in cancer cells. The goal is to develop drugs against metastasizing cancer where galiellalactone is used as a chemical starting point to make new novel, patentable compounds. ...

Tokai Pharmaceuticals

Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company’s lead drug candidate, TOK-001, is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined in one oncotherapeutic....

Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: F...

Theragenics

Theragenics Corporation is a leader in the production and sales of implantable radiation devices ("seeds") used in thetreatment of cancer. The Company produces and sells TheraSeed(R), which is a U.S. Food and Drug Administration (FDA) licensed device, based on the radioactive isotope palladium 103 (Pd-103). The Company received FDA clearanceto market TheraSeed(R) in 1986 and...

Verastem, Inc. Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR a...

HIFU Prostate Services, LLC

At HIFU Prostate Services (HPS), our mission is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS was founded in 2015 by a seasoned management team with over 50 years of exper...

Tokai Pharmaceuticals Inc.

Tokai Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. The company’s lead drug candidate, galeterone, is a highly selective, multi-targeted oral small molecule being developed for the treatment of patients with metastatic castratio...

Mitomics

Mitomics is the world leader in the research and development of mitochondrial DNA (mtDNA)-based biomarkers – a new and innovative approach to the detection of cancer and other disease states. Leveraging its unparalleled insights into the role of mitochondria in cancer, the company is developing an extensive and proprietary portfolio of molecular tests...

Vaxenta Biotechnologies

Vaxenta is a biotechnology company focused on development of novel immunotherapeutic vaccines for the treatment of cancer. The company’s lead product, XenUvaX, leverages similarities between cancer and pregnancy to selectively target the three essential features of cancer: a) angiogenesis; b) metastasis; and c) immune suppression. Currently the compan...

Green Plantchem Company Limited

Green Plantchem Company Limited is a professional plant growth regulator, plant herbal extract and pharm material manufacturer and distrbutor.Our main business include biochemical products and pharmaceutical intermediates, especially in the field of nucleosides and nucleotides. The R&D center at GPC focuses on developing new products, especially PLANT GROWTH REGULATOR ,Herbal extract ,RNA and D...

Us TOO International

Us TOO is a nonprofit organization founded in 1990 that provides educational resources and support services to the prostate cancer community at no charge to help men and their spouses/partners and loved ones make informed decisions about prostate cancer detection, treatment options and related side effects. In addition to more than 200 support groups throu...

Onconome, Inc.

Onconome is dedicated to the discovery, development and commercialization of innovative biomarkers for the early and accurate detection of prostate, colon, bladder and other forms of cancer, including lung, breast, liver, pancreatic and stomach. Early detection is the key to successful treatment. Our serum tests for early detection of prostate and colon cancer and our urine test for bladder cancer...

Genesis Genomics Inc.

Cancer is the leading cause of pre-mature death in Canada, being responsible for almost 1/3 of all potential years of life lost. During their life-time, 2 in 19 women are expected to develop breast cancer, 1 in 18 will develop colorectal cancer, and 1 in 20 will develop lung cancer. Among men, 1 in 9 will develop prostate cancer during their life-time (National Cancer Institute of Canada, 2000).

Precision Biopsy, LLC

Precision Biopsy, LLC is a privately-held startup company formed by Allied Minds, Inc. in cooperation with the University of Colorado to commercialize a revolutionary optical biopsy technology designed to improve the accuracy and reliability of prostate biopsies and the diagnosis of prostate cancer. www.precisionbiopsy.com

Tokai Pharmaceuticals, Inc.,

Tokai Pharmaceuticals is a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven cancers. The company’s lead drug candidate, galeterone (TOK-001), is a first-in-class, multi-targeted, oral small molecule drug being developed for the treatment of patients with castration-resistant prostate cancer...


More From BioPortfolio on "Erratum metabolic regulator PGC1 suppresses prostate cancer metastasis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks